George Kaiser Family Foundation Makes New $772,000 Investment in MaxCyte, Inc. $MXCT

George Kaiser Family Foundation purchased a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 627,536 shares of the company’s stock, valued at approximately $772,000. George Kaiser Family Foundation owned 0.59% of MaxCyte as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Capricorn Fund Managers Ltd acquired a new stake in MaxCyte in the first quarter worth about $5,760,000. Vitruvian Partners LLP bought a new position in MaxCyte in the 2nd quarter valued at about $6,203,328,000. BlackRock Inc. bought a new position in MaxCyte in the 2nd quarter valued at about $3,765,000. Brooklands Fund Management Ltd acquired a new position in MaxCyte during the 1st quarter valued at about $1,538,000. Finally, Kennedy Capital Management LLC acquired a new position in MaxCyte during the 3rd quarter valued at about $3,330,000. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Stock Performance

MXCT opened at $1.38 on Friday. The company has a market capitalization of $142.43 million, a PE ratio of -4.18 and a beta of 1.48. The stock’s fifty day moving average is $1.22 and its 200-day moving average is $0.99. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $1.86.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $6.50 million during the quarter, compared to analysts’ expectations of $6.51 million. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings lowered shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, MaxCyte currently has an average rating of “Hold” and a consensus price target of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.